These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Current status of epirubicin in the treatment of breast neoplasm]. Jiang ZF; Song SC Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):193-5. PubMed ID: 15949413 [No Abstract] [Full Text] [Related]
5. Epirubicin for adjuvant therapy in node-positive breast cancer. Med Lett Drugs Ther; 2000 Feb; 42(1071):12-3. PubMed ID: 10725968 [No Abstract] [Full Text] [Related]
7. Epirubicin as adjuvant therapy in breast cancer. Earl H; Iddawela M Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049 [TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results. Ventura GJ J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014 [No Abstract] [Full Text] [Related]
9. [Polychemotherapy versus monotherapy in metastatic breast carcinoma]. Tanner J; Dunst J Strahlenther Onkol; 1999 Sep; 175(9):471. PubMed ID: 10518983 [No Abstract] [Full Text] [Related]
10. Epirubicin for breast cancer during pregnancy: a case report. Eedarapalli P; Biswas N; Coleman M J Reprod Med; 2007 Aug; 52(8):730-2. PubMed ID: 17879836 [TBL] [Abstract][Full Text] [Related]
11. Plasma and tissue pharmacokinetics of epirubicin and Paclitaxel in patients receiving neoadjuvant chemotherapy for locally advanced primary breast cancer. Hunz M; Jetter A; Warm M; Pantke E; Tuscher M; Hempel G; Jaehde U; Untch M; Kurbacher C; Fuhr U Clin Pharmacol Ther; 2007 May; 81(5):659-68. PubMed ID: 17301739 [TBL] [Abstract][Full Text] [Related]
12. A population model of epirubicin pharmacokinetics and application to dosage guidelines. Ralph LD; Thomson AH; Dobbs NA; Twelves C Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671 [TBL] [Abstract][Full Text] [Related]
14. Epirubicin approved for breast cancer treatment. Miller JL Am J Health Syst Pharm; 1999 Nov; 56(21):2177. PubMed ID: 10565690 [No Abstract] [Full Text] [Related]
15. Synergistic effects induced by cycloprodigiosin hydrochloride and epirubicin on human breast cancer cells. Yamamoto D; Tanaka K; Nakai K; Baden T; Inoue K; Yamamoto C; Takemoto H; Kamato K; Hirata H; Morikawa S; Inubushi T; Hioki K Breast Cancer Res Treat; 2002 Mar; 72(1):1-10. PubMed ID: 12000216 [TBL] [Abstract][Full Text] [Related]
16. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer. Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816 [TBL] [Abstract][Full Text] [Related]
17. Epirubicin as adjuvant therapy for breast cancer. Suh C Cancer Pract; 2001; 9(2):104-6. PubMed ID: 11879287 [No Abstract] [Full Text] [Related]
18. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines. Azab SS; El-Demerdash E; Abdel-Naim AB; Youssef E; El-Sharkawy N; Osman AM Biochem Pharmacol; 2005 Sep; 70(5):725-32. PubMed ID: 16005435 [TBL] [Abstract][Full Text] [Related]
19. Carcinoma en cuirasse of the breast. Carlesimo M; Rossi A; De Marco G; Narcisi A; Cacchi C; Mari E; Persechino F; Camplone G Eur J Dermatol; 2009; 19(3):289-90. PubMed ID: 19557891 [No Abstract] [Full Text] [Related]
20. American symposium looks at new antineoplastic drug. Korcok M Can Med Assoc J; 1985 Jul; 133(1):66-7. PubMed ID: 3891062 [No Abstract] [Full Text] [Related] [Next] [New Search]